← Back to Search

Antiplatelet Agent

tailored antiplatelet selection for Stroke (PASSPoRT Trial)

Phase 2
Waitlist Available
Led By Karen C Albright, PhD, DO
Research Sponsored by State University of New York - Upstate Medical University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

PASSPoRT Trial Summary

This study is evaluating whether a precision medicine approach to antiplatelet selection for secondary stroke prevention is safe and feasible.

Eligible Conditions
  • Stroke
  • Ischemic Stroke
  • Mini Stroke

PASSPoRT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility - Recruitment and Platelet Reactivity
Safety - Bleeding Complications
Secondary outcome measures
Patient-centered Outcomes - Satisfaction

PASSPoRT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment GroupExperimental Treatment1 Intervention
Intervention group
Group II: Control GroupActive Control1 Intervention
Standard of Care group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tailored antiplatelet selection
2018
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

State University of New York - Upstate Medical UniversityLead Sponsor
172 Previous Clinical Trials
27,242 Total Patients Enrolled
2 Trials studying Stroke
234 Patients Enrolled for Stroke
Karen C Albright, PhD, DOPrincipal InvestigatorState University of New York - Upstate Medical University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Personalized Antiplatelet Secondary Stroke PRevenTion
2018. "Personalized Antiplatelet Secondary Stroke PRevenTion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03979781.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top